After scaling back investments in France and pulling the plug on its China trials, Aussie emergency medical solutions company Medical Developments International (ASX: MVP) has a renewed focus, one that helped it reduce its losses from $12.4 million in FY22 to $5.6 million in FY23. The earnings report showed a net gain of $10.3 million
Read More
Perhaps China decided to make its own version of the drug or perhaps it proved that it could do so and fast. Whatever it may be, something told the specialised healthcare company Medical Developments International Limited (ASX: MVP) that it wasn’t a good idea to continue pursuing the country. And so, it stopped. Medical Developments
Read More
Medical device company Medical Developments International (ASX:MVP) has successfully raised $20 million from institutional investors as part of their plans to raise a total of $30 million to fund global expansion plans for its flagship non-opioid painkiller, Penthrox (aka the Green Whistle). Capital raised at the Offer Price of $2.00 per share will be used to
Read More
Australian pharmaceuticals company Medical Developments (ASX: MVP) is set to renew their international expansion targets with greater control having taken back the distribution rights from Mundipharma in both Europe and Australia for their flagship ‘green whistle’ pain reliever – Penthrox. The decision to take back the European distribution rights to 27 countries was made in
Read More
Australian pharmaceuticals manufacturer Medical Developments International (ASX: MVP) has secured approval from the Chinese National Medical Product Administration (NMPA) to commence bridging trials for Penthrox IND, their green whistle pain reliever. The approval is a major step towards commercialisation of the flagship non-opioid pain reliever in China. “The approval of the Penthrox IND by the
Read More
Carried and administered by Australian paramedics for decades, the green whistle pain reliever has been on the Australian market for years but clinical trials in Europe have now revealed Penthrox® to be a superior pain relief product than traditional treatments of morphine (IV), paracetamol, ketoprofen and NSAIDS. Marketed as Penthrox® with the key ingredient of
Read More